Positive Airway Pressure, Sleep Apnea, and the Placenta (PAP-SAP) (PAP-SAP)
Primary Purpose
Obstructive Sleep Apnea, Pregnancy, Obesity
Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Positive Airway Pressure
Nasal Dilator Strips
Sponsored by
About this trial
This is an interventional other trial for Obstructive Sleep Apnea focused on measuring placental morphology, CPAP, placental secretory function
Eligibility Criteria
Inclusion Criteria:
- Pregnant snorers without obstructive sleep apnea, have a BMI >30 kg/m2 at recruitment
- >18 years of age
- <13 completed weeks of gestation (confirmed by last menstrual period or early pregnancy dating ultrasound during qualification)
- Intention to reside locally and deliver at Women and Infants Hospital of Rhode Island
- Ability to give informed consent.
Exclusion Criteria:
- Unable to meet inclusion criteria, Incompetent cervix / cerclage (likelihood of severe preterm delivery affecting study aims)
- Inability to tolerate PAP therapy
- Serious physical or mental illness or condition that would affect participation
- Drowsy driving
- Severe hypoxemia on sleep study
- Advanced cardiac disease or arrhythmias that may benefit from PAP therapy
- Chronic lung disease and / or respiratory failure.
- Twin pregnancies
- Fetuses with congenital anomalies
- Severe hypertension at enrollment
Sites / Locations
- The Miriam Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Positive Airway Pressure
Nasal Dilator Strips
Arm Description
Positive airway pressure and nasal dilator strips during sleep.
Nasal dilator strips during sleep.
Outcomes
Primary Outcome Measures
Alterations in circulating placenta-secreted markers.
Placenta secreted markers that have been linked to preeclampsia as well as angiogenic and anti-angiogenic markers will be measured longitudinally during the course of pregnancy.
Changes in placental histopathology for markers of malperfusion and placental expression of markers
Placental morphology and histopathology will be examined by 3 perinatal pathologists, blinded to each other's reading and to intervention arm. Immunohistochemistry will be used to examine placental expression of certain markers.
Secondary Outcome Measures
Change in 24-hour Ambulatory mean diurnal and nocturnal blood pressure measurements
A 24 blood pressure monitor will be used to measure changes in daytime and nighttime average blood pressure.
Change in a composite of adverse pregnancy outcomes
Pregnancy outcomes defined as gestational hypertension, gestational diabetes and preterm birth (birth prior to 37 completed weeks of pregnancy will be analyzed as a composite outcome
Full Information
NCT ID
NCT02412696
First Posted
January 21, 2015
Last Updated
March 14, 2023
Sponsor
The Miriam Hospital
Collaborators
Brown University, Rhode Island Hospital, Women and Infants Hospital of Rhode Island, Brigham and Women's Hospital
1. Study Identification
Unique Protocol Identification Number
NCT02412696
Brief Title
Positive Airway Pressure, Sleep Apnea, and the Placenta (PAP-SAP)
Acronym
PAP-SAP
Official Title
Placental Role in Mediating Adverse Outcomes in Obstructive Sleep Apnea
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
June 1, 2015 (Actual)
Primary Completion Date
August 1, 2020 (Actual)
Study Completion Date
December 1, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The Miriam Hospital
Collaborators
Brown University, Rhode Island Hospital, Women and Infants Hospital of Rhode Island, Brigham and Women's Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study is testing the hypothesis of whether continuous positive airway pressure (CPAP) therapy improves placental histopathology and secretory function. The main aims of the study are to identify shared mechanisms between obstructive sleep apnea and preeclampsia, both common highly morbid conditions.
Detailed Description
Patients will be recruited from multiple community and hospital-based practices that care for pregnant women. Subjects will be given a physical exam, have measurements taken, answer questionnaires and then will be screened using a home sleep apnea test (HSAT) Type III device. Those diagnosed with Obstructive Sleep Apnea will then be randomized to one of two groups (below).
Both groups will have:
blood testing for placenta-secreted circulating markers
placental histopathological and immunohistochemistry examination of placental expression of markers.
Both groups will answer sleep and mood questionnaires, have blood pressure, blood glucose and activity / sleep watch monitoring and will receive an educational session on pregnancy health.
Randomization groups include:
Nasal dilator strips: Participants receiving nasal dilator strips will be monitored by need for refill of supplies and periodic phone calls.
CPAP + nasal dilator strips: Subjects randomized to positive airway pressure (PAP) therapy will receive auto-titrating PAP. Pressure requirements will be monitored remotely and pressure modified as needed. PAP adherence will be determined subjectively and objectively. This group will also receive nasal dilator strips as described above.
All subjects will receive small gift incentives such as baby-related items. Monetary incentives will also be issued at data collection points.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obstructive Sleep Apnea, Pregnancy, Obesity, Preeclampsia, Sleep
Keywords
placental morphology, CPAP, placental secretory function
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
262 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Positive Airway Pressure
Arm Type
Active Comparator
Arm Description
Positive airway pressure and nasal dilator strips during sleep.
Arm Title
Nasal Dilator Strips
Arm Type
Placebo Comparator
Arm Description
Nasal dilator strips during sleep.
Intervention Type
Device
Intervention Name(s)
Positive Airway Pressure
Intervention Description
Auto-titrating PAP + nasal dilator strips during sleep
Intervention Type
Other
Intervention Name(s)
Nasal Dilator Strips
Intervention Description
Nasal dilator strips
Primary Outcome Measure Information:
Title
Alterations in circulating placenta-secreted markers.
Description
Placenta secreted markers that have been linked to preeclampsia as well as angiogenic and anti-angiogenic markers will be measured longitudinally during the course of pregnancy.
Time Frame
up to 6 months
Title
Changes in placental histopathology for markers of malperfusion and placental expression of markers
Description
Placental morphology and histopathology will be examined by 3 perinatal pathologists, blinded to each other's reading and to intervention arm. Immunohistochemistry will be used to examine placental expression of certain markers.
Time Frame
Placenta collected at time of delivery
Secondary Outcome Measure Information:
Title
Change in 24-hour Ambulatory mean diurnal and nocturnal blood pressure measurements
Description
A 24 blood pressure monitor will be used to measure changes in daytime and nighttime average blood pressure.
Time Frame
Prior to randomization, then at approximately 3 months, and 6 months later
Title
Change in a composite of adverse pregnancy outcomes
Description
Pregnancy outcomes defined as gestational hypertension, gestational diabetes and preterm birth (birth prior to 37 completed weeks of pregnancy will be analyzed as a composite outcome
Time Frame
8 months, delivery and 2 weeks postpartum
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Pregnant snorers without obstructive sleep apnea, have a BMI >30 kg/m2 at recruitment
>18 years of age
<13 completed weeks of gestation (confirmed by last menstrual period or early pregnancy dating ultrasound during qualification)
Intention to reside locally and deliver at Women and Infants Hospital of Rhode Island
Ability to give informed consent.
Exclusion Criteria:
Unable to meet inclusion criteria, Incompetent cervix / cerclage (likelihood of severe preterm delivery affecting study aims)
Inability to tolerate PAP therapy
Serious physical or mental illness or condition that would affect participation
Drowsy driving
Severe hypoxemia on sleep study
Advanced cardiac disease or arrhythmias that may benefit from PAP therapy
Chronic lung disease and / or respiratory failure.
Twin pregnancies
Fetuses with congenital anomalies
Severe hypertension at enrollment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ghada Bourjeily, MD
Organizational Affiliation
The Miriam Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Miriam Hospital
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02904
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
34999843
Citation
Sanapo L, Bublitz MH, Bai A, Mehta N, Messerlian GM, Catalano P, Bourjeily G. Association between sleep disordered breathing in early pregnancy and glucose metabolism. Sleep. 2022 Apr 11;45(4):zsab281. doi: 10.1093/sleep/zsab281.
Results Reference
derived
PubMed Identifier
33481418
Citation
Facco F. Sleep Duration, Sleep Timing, and Sleep Disordered Breathing-Associations With Obesity and Gestational Diabetes in Pregnancy. Clin Obstet Gynecol. 2021 Mar 1;64(1):196-203. doi: 10.1097/GRF.0000000000000587.
Results Reference
derived
Learn more about this trial
Positive Airway Pressure, Sleep Apnea, and the Placenta (PAP-SAP)
We'll reach out to this number within 24 hrs